Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus.

Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity. Proc Natl Acad Sci U S A (2011) 1.66

Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci U S A (2010) 1.65

Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin (2010) 1.63

Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med (2008) 1.54

The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration. J Neurochem (2008) 1.48

Blood biomarkers of ischemic stroke. Neurotherapeutics (2011) 1.34

The search for lupus biomarkers. Best Pract Res Clin Rheumatol (2009) 1.26

Neuropsychiatric systemic lupus erythematosus. Curr Neuropharmacol (2011) 1.04

Selective involvement of the amygdala in systemic lupus erythematosus. PLoS Med (2006) 1.03

Moving towards a cure: blocking pathogenic antibodies in systemic lupus erythematosus. J Intern Med (2011) 0.98

Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J Neurol (2011) 0.97

Brain-reactive antibodies and disease. Annu Rev Immunol (2013) 0.94

Stroke patients develop antibodies that react with components of N-methyl-D-aspartate receptor subunit 1 in proportion to lesion size. Stroke (2013) 0.86

A model for lupus brain disease. Immunol Rev (2012) 0.85

Possible novel biomarkers of organ involvement in systemic lupus erythematosus. Clin Rheumatol (2014) 0.83

Diagnostic and pathogenic significance of glutamate receptor autoantibodies. Arch Neurol (2008) 0.82

Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. J Neural Transm (Vienna) (2014) 0.80

Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Front Immunol (2016) 0.80

Antibodies and the Brain: Lessons from Lupus. J Immunol (2010) 0.79

Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev (2017) 0.78

Estrogen receptor alpha deficiency protects against development of cognitive impairment in murine lupus. J Neuroinflammation (2014) 0.77

Effects of prolonged treatment with memantine in the MRL model of CNS lupus. Clin Exp Neuroimmunol (2012) 0.77

Antibodies as Mediators of Brain Pathology. Trends Immunol (2015) 0.77

Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system. J Neuroinflammation (2016) 0.76

Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus. Lupus Sci Med (2015) 0.76

Gene expression profiles in a rabbit model of systemic lupus erythematosus autoantibody production. J Immunol (2010) 0.76

Anti-N-Methyl-D-Aspartate Receptor Encephalitis in a Patient with Systemic Lupus Erythematosus. J Clin Neurol (2016) 0.75

Autoantibodies to NR2A Peptide of the Glutamate/NMDA Receptor in Patients with Seizure Disorders in Neuropsychiatric Systemic Lupus Erythematosus. Mediators Inflamm (2017) 0.75

All-Trans-Retinoic Acid Augments the Histopathological Outcome of Neuroinflammation and Neurodegeneration in Lupus-Prone MRL/lpr Mice. J Histochem Cytochem (2016) 0.75

The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum (1992) 14.73

Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med (2003) 10.82

Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol (1982) 9.73

Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature (1986) 7.10

A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med (2001) 4.35

The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci (1990) 4.34

Structure and function of glutamate receptor ion channels. Annu Rev Physiol (2004) 2.29

Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol (2003) 1.99

The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology (2001) 1.96

Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci (2001) 1.91

Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci (2000) 1.91

Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem (2003) 1.67

Constructing proteins by dovetailing unprotected synthetic peptides: backbone-engineered HIV protease. Science (1992) 1.54

Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum (1996) 1.43

Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua. Neurology (2003) 0.94

Neurofilament antibodies in systemic lupus erythematosus. J Rheumatol (1986) 0.91

Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum (2004) 0.90

The NMDA receptor complex. Fundam Clin Pharmacol (1993) 0.89

Cognitive impairment in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus: a population-based neuropsychological study. J Clin Exp Neuropsychol (2003) 0.89

Ribosomal P antibodies and CNS lupus. Lupus (2003) 0.87

Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome. J Clin Immunol (1993) 0.84

Molecular cloning of cDNA encoding the p70 (Ku) lupus autoantigen. J Biol Chem (1989) 2.50

Dependence of the chemical nature of antibodies on the net electrical charge of antigens. Proc Natl Acad Sci U S A (1966) 2.25

Antigen-specific thymus cell factors in the genetic control of the immune response to poly-(tyrosyl, glutamyl)-poly-D, L-alanyl--poly-lysyl. J Exp Med (1974) 2.19

Antigen-specific T-cell factors in the genetic control of the immune response to poly(Tyr,Glu)-polyDLAla--polyLys. Evidence for T- and B-cell defects in SJL mice. J Exp Med (1975) 1.98

Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci U S A (1988) 1.91

CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood (1997) 1.89

Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J Virol (1991) 1.83

Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med (1983) 1.79

Contribution of different cell types to the genetic control of immune responses as a function of the chemical nature of the polymeric side chains (poly-L-prolyl and poly-DL-alanyl) of synthetic immunogens. J Exp Med (1972) 1.75

The nature of the antigenic determinant in a genetic control of the antibody response. J Exp Med (1969) 1.74

The genetic control of antibody specificity. J Exp Med (1969) 1.58

In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest (1988) 1.57

The beneficial effect of the estrogen antagonist, tamoxifen, on experimental systemic lupus erythematosus. J Rheumatol (1994) 1.56

Thymus-independence of slowly metabolized immunogens. Proc Natl Acad Sci U S A (1972) 1.52

Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood (1996) 1.51

Ginseng improves pulmonary functions and exercise capacity in patients with COPD. Monaldi Arch Chest Dis (2003) 1.49

CD24 is a marker for human breast carcinoma. Cancer Lett (1999) 1.45

Primary empty sella: cause of visual failure or chance association? Eye (Lond) (1998) 1.38

In vitro and in vivo induction of effector T cells mediating DTH responses to a protein and a synthetic polypeptide antigen. Cell Immunol (1979) 1.38

Genetic control of immune responses. Curr Top Microbiol Immunol (1972) 1.34

Contribution of bone marrow cells and lack of expression of thymocytes in genetic controls of immune responses for two immunopotent regions within poly-(Phe,Glu)-poly-Pro--poly-Lys in inbred mouse strains. J Exp Med (1971) 1.31

Cellular basis of the genetic control of immune responses to synthetic polypeptides. I. Differences in frequency of splenic precursor cells specific for a synthetic polypeptide derived from multichain polyproline ((T,G)-Pro--L) in high and low responder inbred mouse strains. J Exp Med (1970) 1.31

The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum (1989) 1.28

The role of thymus cells in the immune response to poly(Tyr, Glu)-polyD L Ala--polyLys as a function of the genetic constitution of the mouse strain. Eur J Immunol (1974) 1.24

T-cell hybridoma bearing heavy chain variable region determinants producing (T,G)-A--L-specific helper factor. Nature (1980) 1.19

Genetic regulation of delayed-type hypersensitivity responses to poly(LTyr,LGlu)-poly(DLAla)--poly(LLys). II. Evidence for a T-T-cell collaboration in delayed-type hypersensitivity responses and for a T-cell defect at the efferent phase in nonresponder H-2k mice. J Exp Med (1980) 1.16

Thymus independence of a collagen-like synthetic polypeptide and of collagen, and the need for thymus and bone marrow-cell cooperation in the immune response to gelatin. J Exp Med (1974) 1.15

Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. J Immunol (2000) 1.15

Genetic regulation of delayed-type hypersensitivity responses to poly(LTyr,LGu)-poly(DLAla)--poly(LLys). I. Expression of the genetic defect at two phases of the immune process. J Exp Med (1980) 1.11

Immune response of mice to nucleic acids: strain-dependent differences in magnitude and class of antibody production. J Immunol (1973) 1.10

Resolution of mouse and human immunoglobulin G into two fractions by chromatography on diethylaminoethyl-sephadex. Relation of mouse antibody type to the antigen charge. Isr J Med Sci (1969) 1.10

The role of anti-idiotypic antibodies in the induction of experimental systemic lupus erythematosus in mice. Eur J Immunol (1989) 1.10

Antibody response of inbred mouse strains to ordered tetrapeptides of tyrosine and glutamic acid attached to multichain polyalanine or polyproline. Tyr-Tyr-Glu-Glu is a major determinant of the random poly-(Tyr, Glu)-polyDLAla--polyLys. J Exp Med (1974) 1.09

The effectiveness of topical diclofenac in relieving discomfort following traumatic corneal abrasions. Eye (Lond) (1997) 1.09

Analysis of the biological functions and fine specificity of (T,G)-A--L specific T cell clones. Immunobiology (1986) 1.08

Pathogenic idiotypes of autoantibodies in autoimmunity: lessons from new experimental models of SLE. FASEB J (1990) 1.06

Direct binding of a myasthenia gravis related epitope to MHC class II molecules on living murine antigen-presenting cells. EMBO J (1989) 1.05

The effect of genetic control of immune response to synthetic polypeptides on the response to homologous DNP-polypeptide conjugates. Immunochemistry (1969) 1.05

The autoimmune response of different mouse strains to T-cell epitopes of the human acetylcholine receptor alpha subunit. Immunology (1990) 1.05

[Strain-dependent differences in the specificity of antibody responses toward lysozyme]. J Immunol (1971) 1.04

Role of antigenic structure in cell to cell cooperation. Proc Natl Acad Sci U S A (1976) 1.04

Progression from acute to chronic disease in a murine parent-into-F1 model of graft-versus-host disease. J Immunol (2000) 1.03

The nature of murine immune response to nucleic acids. J Immunol (1975) 1.03

Linkage between immune response potential to DNA and X chromosome. Nature (1974) 1.03

Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol (2002) 1.02

Cellular basis of the genetic control of immune responses to synthetic polypeptides. II. Frequency of immunocompetent precursors specific for two distinct regions within (Phe, G)-Pro--L, a synthetic polypeptide derived from multichain polyproline, in inbred mouse strains. J Exp Med (1971) 1.02

Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J Immunol (1997) 1.01

Antigen specific T-cell helper factor cross reacts idiotypically with antibodies of the same specificity. Nature (1979) 1.01

Antigen-specific T cell factors: a fine analysis of specificity. J Immunol (1977) 1.01

In vitro correction of antigen-induced immune suppression: effects of histamine, dibutyryl cyclic AMP and cholera enterotoxin. Cell Immunol (1974) 1.01

The genetic regulation of the induction of experimental SLE. Immunology (1990) 1.00

Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc Natl Acad Sci U S A (1997) 1.00

(T,G)-A-L specific immune response potential and HLA typing of Israeli patients with systemic lupus erythematosus. Clin Exp Immunol (1985) 0.99

A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses. Proc Natl Acad Sci U S A (1997) 0.99

Cross-reactive idiotypic determinants on murine anti-(T,G)-A--L antibodies. J Immunol (1978) 0.99

In vitro studies on H-2 linked unresponsiveness. 1. Normal helper cells to (T,G)-A-L and GAT in low and non-responder mice. Immunology (1977) 0.99

Beta 2-microglobulin-deficient background ameliorates lethal phenotype of the TGF-beta 1 null mouse. J Immunol (1999) 0.99

The role of thymocytes and bone marrow cells in defining the response to the dinitrophenyl hapten attached to positively and negatively charged synthetic polypeptide carriers. Cell fractionation over charged columns. J Exp Med (1973) 0.99

The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Immunol (1995) 0.98

The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci U S A (2001) 0.98

Cellular aspects of the inverse relationship between the net charge of immunogens of antibodies elicited. Proc Natl Acad Sci U S A (1970) 0.98

Role of MHC class I molecules in autoimmune disease. Crit Rev Immunol (1997) 0.97

Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed Pharmacother (2005) 0.97

The role of the 16/6 idiotype network in the induction and manifestations of systemic lupus erythematosus. Int Immunol (1993) 0.97

Antigenic competition and genetic control of the immune response. A hypothesis for intramolecular competition. Cell Immunol (1973) 0.97

HCV hepatitis associated with anticardiolipin antibody and a cerebrovascular accident. Response to interferon therapy. J Clin Gastroenterol (1997) 0.97

Engraftment and development of human T and B cells in mice after bone marrow transplantation. Science (1991) 0.96

Genetic control of immune response. The dose of antigen given in aqueous solution is critical in determining which mouse strain is high responder to poly(LTyr, LGlu)-poly(LPro)--poly(LLys). J Exp Med (1975) 0.96

The role of the human anti-DNA idiotype 16/6 in autoimmunity. Clin Immunol Immunopathol (1989) 0.95

Heterogeneity of the light chains of rabbit immunoglobulin G fractions and of a series of antibodies directed towards antigens of differing complexity. Immunochemistry (1967) 0.95

Immune response potential to poly(Tyr,Glu)-poly(DLAla)--poly(Lys) of human T cells of different donors. Proc Natl Acad Sci U S A (1981) 0.95

The importance of the pathogenic 16/6 idiotype in the induction of SLE in naive mice. Scand J Immunol (1990) 0.95

Epitopes of the p70 and p80 (Ku) lupus autoantigens. J Immunol (1991) 0.95

Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia. J Urol (1995) 0.94

Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs. Proc Natl Acad Sci U S A (1993) 0.94

Cellular studies of the genetic control of immune response toward the loop region of lysozyme. J Immunol (1973) 0.93

Clinical comparison of the measurement of the IOP with the ocular blood flow tonometer, the Tonopen XL and the Goldmann applanation tonometer. Acta Ophthalmol Scand (2001) 0.93

Palmar fasciitis and polyarthritis associated with ovarian carcinoma in a young patient. A case report and review of the literature. Clin Rheumatol (1996) 0.93

Genetic control of the murine cell-mediated immune response in vivo. II. H-2 linked responsiveness to the synthetic polypeptide poly(Tyr,Glu)-poly(DL-Ala)--poly(Lys). J Immunol (1975) 0.92

Immunological unresponsiveness induced in adult mice to synthetic polypeptides built on multichain polyproline and multichain polyalanine. Immunochemistry (1974) 0.92

Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. Proc Natl Acad Sci U S A (2000) 0.92

Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex. Surgery (1992) 0.92

Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3-based peptides of a pathogenic autoantibody. J Clin Immunol (2000) 0.92

Sex hormone involvement in the induction of experimental systemic lupus erythematosus by a pathogenic anti-DNA idiotype in naive mice. J Rheumatol (1990) 0.91

Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol (2003) 0.91